Abstracts Vol. 1 [International Conference on AIDS (11th: 1996: Vancouver, Canada)]

Track B: Clinical Science

Mo.B.l239 - Mo.B.1243

Results: ( )ire lunir 11-11rid niety I r errsaepes wre re ii yze-,1.2" (8'1/ I /1).Tihe psit pr ul ewi ~nsinn IrenA/a) AS the s
(26.2 % n -I I 'ler s I fri.I C I. 2(13890) O [Irf eti i
(5/84)Ir IIn hc, irte in hr equiernt S fseloialpatternrs 'Awl
IKAO /() ( 15.1 'x) /Il Il/I l 5 ()HKsAII(-)1(23.6~(')
1lIlA/If 6. 3"h).FFpaitilit ii llrliiiestat/ll SIwreIer i
If h er i)&)();r Ii rr 1/rItl F1V ir fr(ion
Conclusions: Prr- i1 rr 0 II I ( sroloical r cr5 rs high anInors rcda c tAl) eerlrne-i otvdo, r
wifrrii ifie pe l iR in the I/ill-cuty (06~ in blood1(donorsI). Sc)
I his, pop[1lationrs uitituites anll iefs/r1loofeIc (/reseI/Si/ 1o1f11vira
part of the in r siistInce of these patientsthre tedsif 1tear
orde1 r ytil r fir/Aw1(o frevel/t ifrlHod and /3sI/i-l f11lrtsritt:
E. 5 Vii F St 111 I ir Loez 1693/20-3. Mortevideo 1 II 1,0 ti lugiI
(598) 2 (6)521, fax.(59ff) -2 80~l1 I iimail. p /1(V(S. / con/u%
Mo.B. 1239

/ f l l

(Ir
I; F! ( ) l

ce A/as Patienits: SI/ f/I Ce stuiedrIIf153 fpat/ients 3/IsitivI/for danti IHIV (tff-blown AIDS: 23%, mean
)itieists L i 3:/Ill /S /1 Inl3, AIDS 388/n3l) Ind Ilnti HCV (HCKV RNAt: 15%). They were tall
11E% f /I-, A-i 31IBS60, Intli HBs 1118 FBc 47,110o1H1V 46). History of fVD use was peesent in
/F (+ ), 8) al~/ i hr l),y had beern perfornmed ini73 rIses (20 CPH, 29 CAH, 24 Cirehosis).
BrA) (1), Methods: f113111rnd (DV mairkhers testerd by RfA (Abbott), HIV aisd HCV lbs by ELISA with
9. %)3, r i 06 e,r, fi I /)t /RIBA coirm/s/pIetil/f I BVDNA by Dot Blot, I DVRNA by Dot Bfot,
1 it 'f /d 33KII/ -1RnSteI//IPC R3lter Suetca ef Extritois.
1/;pee Results. f-fk f/f IA A/Ias 5 sign tfytlI/ orereiietly detected (p-0,0041f8) Inrong anIti,)roiips ~ / 2 andf patients with no HBKV mairkeis (50%), thsan anti HBs arid HBe+ cases
i'tf HB~. i/I. I fir, smnee was indrpendI/rt ol tfseitodfe of contantion and was obseived in5
rtelld lut. / / Pt V pItier tS as wefi as aitofrill3111bfowis AILDS sses despite a sigiiclant lowee:r,,io. As prii I )ti' I ii V RNA (29/50%, p-O0,02526). CP1H had lowei (p-0,01985) ti ansaminaset
i If iis in f-,, +,tf r- 5ff?01I/orirrsosis (71nw 17 Seheffe). Livei lesions were niethee related to H-BV
ion lit/I r 11ii / ), i i)fj 32.V RNIA detectilontorIIAIDS evolution.) he highser snshsei of CD4
oh-wi C 11111.1/, anti HBe-4 patients (antti LIBe 3/3/anti HIBs and lH~e 232/no HBV 265,
23111 1/n 5i lysc~htIfe was related to the lowei numsbee of AIDS eases present in that group.
fpne Conclusions: Am ong patiensts eorltfeced wills I IV and HCV, there is an interaction
li-f vi ini<raj ri(.,,,ion of hepati(is r ti rs Ind AIDS pirogression. Oue results suggest that at
loe c'S f. ti r Il~nosuppiession, 11CV replecation is not influeneed by HBV expression and
"H pp!e ~,ni fI1lBs productios. Full-blown AIDS may be assoeiated with HBV reactivation,
131% / e 7/I:pssron and HCV RNSA repression.This btlance does not signifieantly rnfluec ie ii I/alls pirogiressionis An atlteirnative interpr etation of an influetsee of viIral eornfe _I - n i IV 1disse proegiression would11need a paltient follow- up.

REACTIVATION VS REINFECTION OF HEPATITIS B IN HIV iSkRdPOSl] IVE
INDIVIDUALS WITH PREVIOUS NATURAL IMMUNITY TO lI/K.AI FIS B
13 re, U Jr ire MFlongs,21. W2ilfordrIH1l1lIMeillCenlIi, 1.5kl,i / 1IfI',
Objective: hle- fr s if irti 1IlK imai)ocrrriin 8K~rsf 3HIV p tr I ii /.I lIipi tB(Fy) h eeomn fsusqet1isA ecl..
FlIfI wiir/l il ili tier 2laii H IV fir it I/ i letie n If irnattil.i - - /1i
ha 1isolated a1iHfB1 'eropof/eliitt1, 111111sufbsequenitl/ becanme' I / / i Is
si-r Ir/gis in our HI1V cehrtIi were resvewed to determrsise tIhe an3
hirequerr1and elir cn I I- /tie ofi sf ofted inti-H3Bc.sei ope iti / -I fI / -II
itn f I I Ag seeofositrvty po.f sit/tral imrmunity to 11KBV.
Methods: 1lB s Sef rores efbtaIifd rlutirnI/y eveiry 2 to f12 1it.Ii /
/aifiintscoil/effed/Iin the3US/I F IV IV -it /111 Histor y Cofhoirt Fit o/ - //
sI/ertiVely Irtviewed.
Results:Piive FIBlV serrfogre /occI/led it /91/13411(59%) I-it / %lF 1 is~i
(possitive 1afti II 3 i i d 11( IHB5) was reported in -60//91458 f- sr- - i
los osf lnitI 1135 Ocrlil/i'errat I/IaItisne occasion/ in '/7/460 (f7 p'I -.I e
con wa lit io51t 311edicfive o/1loss ef oIi tFlKs (48/ /S 31) eel s/mI, )/Ili - 6Ii
paitwit natral tI f1113 / imiuiylo st 1lnt/iFIB5sIiropositivity I f.,! incle f
1IlK A1'iisn/f5 /511Ve. A tIc/i iih /4(0 (.9~) 1patents with 11,15/I - I hi -sily -y
fur ntly fsecInm/e po/sivfoi both IlB5 Ag arnd nti-HBs. Resviwicr / 1.% f/li ci
solil i/c ti. HP1)(3K1on t feastfone orcIsioni 'eveafed I) 97 indivirl iI if.lk/-ritypsiieat FIssrlgis )2 it nemttnl cw,,1lo
siilae taIIlti-FllK(, 115d14) 1in ratinllfromrru ral imisunity tII 9ff d.Fa ipCocuinIsledntFBin-IVnorsuycmolyep w;: c c
I 13B 'evels Iinindi ifiulsit/lh I/preiur ituiral lHBV mimiret1, 8 -, 2A; / - 3 1s
lesel F1KV ilt i errati i. Simslrf to /other studie/,anti-HBs lossAI -
01cuiree-i f i-fIKs Arseropr/i/Sit, /n 3 prevrirusfyr/ituril 21K.t, i )r f P
rsentith-Irirelapse oir-lI/i/lI/ion Thr-f pstieI/I/s3postive for1::!IfI -,,
i/eslikeIyhf/lI/srintslKFV reinfection iAtfhinothue BV sut ViashI f/fA
sist /11t KN FW's yertprst fl1F-IBVrIeoery (pesitive 11nt iHBs). Ill Of
wfsihichsenar- /oild eresen t liwow rvel11KV irsectivity) and (Ise I I ff I / - /7o~ty
poist ii til i I/iiit. wtr ranits Is-vai n of rsvaccinse reeortr I II - rI I
JIl/i eMf.ii' 2sa, f1eltf 1 21f/f eri 15DFr, Ste 1, 1F a irl AFB, I/3 t 1-1O
675 '2.2,1 ux:2 0/(7 f/f/

duo theis,;hep itis
IB lBo ss,

/~ 5 / /1 / 1 / ppe Mra, Depst. Infectils arid Tiropical Diseases, La Sapienza University
/ f / -ic lirif,0:r to Volite del Pofrlinree 155, 0116I Rorre, ItalyTel.. 39 6 4 456388
Fax 3 ) 6 fI 8 19

'J
I"',l
'I
l
i,
c
t.

of develop- Mo.B. I1242
HEPATITIS C PREVALENCE, DEMOGRAPHICS AND SELECTION CRITERIA FOR
)14 /9 INTERFERON THERAPY IN AN URBAN HIV-POSITIVE COHORT
I/re retro pu-is/I fur, IrtHi, Ross, JackrW. Hiartford IHospital, FHartford, CT USA
Objective: Fo determrine the seroprevalence of hepatitis C, to deseribe the demographics of
/ rstir/ity thlie 1/ osii e individulals and to proposse selection citleria for alpha-interfer on therapy in,bsI/cl/eist In iii 1 11/hIV p sitiVe poplfationi.
-CD4 Methods: lDwti / -[ectiVe char t review was doise cn 131 HIV + patients with CD4 counts
(.7%I),e r ('lthain?0Or cunsms to determnine the seroiprevalenice of hepatitis C. HIV riuk, gender,
-becanie age, liver/ni i/tests, curilent subistance abuise and i/on-conspliance with clinic care were
iubse- I/a iii n tichepatitis K + undividuals.
rIs with an Results: Fri /t;I riee sublects (32%u) were seronegative (SN) foerIsepatitis C and 88 subfects
is or inter- (66%) wA/I/ic IIpositiVe (SP) foerlhepatitis Ci. In the SP grouip 63 (72%v) were male and 25
I22 with (28%)3 wetre fersale. Fifty-four (61 u%) were Latino, 23 (262%) were black, and I I (I 3%) were
>tivity whirfe.Risk facors were: IUD=76 (86%), heter osexul=l7 (8%u), gay=/2 (2u%), gay/IDHA=2
ow anti /2 %0),ard ii r i hIra- I (<S I %).Thte mean C D4 corunt was 509 cumin (range 21I2-1I088);,'nt low a11,1the-'eanCsre A/as 36.7 (range 22-62). Sisty -one (69%) had abnormal transaminases.
The F 'ty (4/-Y."A)CII/ Ictive substance ab/Isers. Non-compliance ( _2 consecutive "no shows" or
isay reIp- tofta of 3 ''noi.shows") occur red in sixty (68%v) of patients.
I//ti-113 Conclusions: fir this inner city I IIV clinic pop/Ilation with CD4 > 200curssn, hepatitis C
A m/1y per- err c valcer/rw.ith elevated traansinases is comnmon. Non-compliance and active subi/ti -HBs (of stanre-.r Ii.ns ym be barrirers to alpha-interferon ther apy. A simple protocol with
recurrience iic I 0sc~/c,l1io n criteria for treating sepatitis C with alpha-interferon w il be presented.
ide spoils- N1fir et (Fl ir i Adult Ambulator y HeaIlth Center:,IHartford Hospital. P0 Box 5037,
IHartfor(1,tI; / )-)A 06102-5037 Tel:/(860) 545-243/ Fax: /800) 545-425o

tIel: 210

vO
0
N
cm
0
to
0
cv
a)
96

Mo.B. 1240
RECURRENT HEPATITIS B INFECTION IN PREVIOUSLY IMMUNE116HIV INFECTED
PATIENTS
Mj~erckjS-1,Ki/Boy l I/I.A,ir / iis (2
Newt/orki r siti /CrsifMiclruCewrterr I/i/tillfor Spectril >oic 'if/h, r.NY,HUSA
Objective: VWe pi / l Ifir c' es' ofir- stecenwt, syr/pt//imitic h _tmi I jI IV ifeted

Methods: KrifhI/il andf i rlic ipitest ing /o2thuree pItrenits A/,( -
cons1/istentI will) icteIhept itii.
Results: lesis ibtainiedl on eac)hil/rti t ten/iry It / olipir81rai
111 ti/I/antigen /I ils iL 3aniibiod/y/to cireiintigen (1-IBrab) aid a'
(I ILsatg(.inicire wsof/pioer i'ecion Iwithimi sty. Serologic Ii11
Iurung Ithe heIepisode1'reveled prser e oef hIK-ig slid, in i I- M
(I I~e- IftIAllk-eied isk iiIf1ctrsr Iaiue Icreirnfection. In (we pa 1'yl
Live during1)1tle il/lie f/I/se or) ilferIiin;in /one/I IIsab becarmie / / iti
oface ih iti ts A inilection1. Cournt er/ ipatitis C ifectronsaueIr c iIte111'rises in i laisillI rwiicuIsreII/u riwd to b Isel nw I ('/
itwi / runt illniiis). 3I1/l 5/12I gtie I ew letinto fsyr/pte/I/s the Irc t It ur"ivi 'IlK p.
Conclusion: iWA/c. iI irf tiftithese' I'patintshar fI/Iruresecii
rdests'ri iurevurdercefi) ii u i/1. [ifhysicrin, cetinrg for II
ii g iuti clinicalf v o/rioeicral c-vid1en1ce1 Ffspatitis s1/ould ite.;- -
ruli l- fr - ~lBls f the presenrcluf B ii.

s I 1tibody to
)I 1.i/n ceantigen
il if Fre patients
i --,A, u itigenen/ra
I Ifs! - i I 1,1ned posit I!,we hid evidence:". /, 1in two.A ll had
(: lifieid of an
ii;.in;; utieruts rerertI
-p I S il/ Ife/tron
/ ir 'it. preseist
i/r i nIfi thue differ
Mo.B. 1243
WHEN TO PRESCRIBE AVAILABLE PROPHYLACTIC TREATMENTS OR TO BEGIN A
SYSTEMATIC SURVEILLANCE?
/ / 1 53.gief~i1,.MaIry-Krause Mur nefleu the Clinical [pidemiology Group from Centres
d'ir uferintIn usItide Soinss de f'Imnrodeficuorsre hunsaune. IiB3[, INSERM 5C4, Paris, Frtnce.
Objective: 3d estimate the risk of Kirst occurs ence of HIV-related diseases, foe which pro/1 yl-,s ire(,Iaal able, depending on thre CD4 count level
Methods: The Fr ench Clinical [pidensiology DartabaIse 011 HIV seropositive subiects followed
irs hosp[talifWAsIstarted in 1989 in n/ore than 50 hospitals in France.The standardized data
colect inf.rm includes characterization of exposiuie group, values of usulal biological marken-. rin ica1/5 ritessasuons of HIV-irsfection (physicians' diagnosis), nature of treatments deivr I, iltenlif. laion of clinical truths in which the patiens was included, and death and ciuse of
deathIfsI /3/ / t5. in the medical records. A follow-up~ form ussrised at each visit or hospital
I srnis ic. I shei <' a clinical nmanifestation/ of HIV infection us reported, a new treatment us
prei rue 1, oit least every 6 months. As of December 31, 1995 data relative so 44 768
sen Ispi ti.I/ ill ects are included in the database with a 20 month mean follow-up time.
Peeple / e conirsder ed at rush of developing a disease in a given CD4 count categor y as
fe/ispas thsemn I 1r counit temnsred in the category oe urstil occur rence of the disease orIoas t f-i f). whichever occurired hrst.Thus analysis was performed over the period
I1989-f 19, eond analysis will estinmate she risk septirItely before and after 1992, in
crieIr t I into111 accourst the cifl/Ision of the prophylactic tr eatnments.
Results: Itn-nlcuce rate of first occrrence of selectedl HIV/-related disetses pee 1000 peesosas h,, ('Ii1 11.4+-coctrit/msl

S in u-hF/rTii Ffh 1L) Fw i 1< F Ifi sirt il522/8/I 58th/F 1,fIl i
T,1h 2 116 1/8I us0/Fi: 72/6-84/S.

/D'1 / CMS/ diseatse PC P Toxop asisosus Atyp. Mycob.
disease
l 2.I I
6 9 4 2

Tuberculosis
5
/4
31
Si
57

Mo.B.1241
HCVVIRAEMIA IN HIV POSITIVE PATIENTS NEGATIVE FOPI I IhS A(.
LV Soil - t.L/st//t'' I 1/, ' 1) ii oIM P,// - ii / -IsFiri
Hii ii '' l "ll/ I II I I 1.pit /1,i, w I luo c' 1DieufL / r l;I in r~r eI11ll/s ii Ii,. i/r' 1/~tI.1' i f i ~Ii nrz -. i Ital
Ainm: 1 iin)Il 1/rr n.1// - nlrenil ley iinc i nf3/ II\ /am/u
HIV 21 1/'

Ufs /8
I / 5/9

32
98
1)6

9 6
/1/ 23
192 126

Conclc:ruone /( I/ic-bals/3111- I Iresulls, 5/s/eli slur sin veil ll e ef /:MV etiusutus rid/or
C [ IV Si - -,s should bwguin/h/ O O 00 [1-1/ ri/, h./ile Per- atyp/icalnsycsbarteua disc' I -rOR i( useuuaded C L)4 oe nteirs itlco/uldI be ived as 50 CL34 amss.